2017 - IHE

Steen Carlsson K & Toresson Grip E Nationella riktlinjer för vård och omsorg vid demenssjukdom – Stöd för styrning och ledning. Medverkan i Stockholm: Socialstyrelsen 2017
Artikelnummer:2017-12-2
Steen Carlsson K, Andsberg G, Petersson J and Norrving B Long-term cost-effectiveness of thrombectomy for acute ischaemic stroke in real life: An analysis based on data from the Swedish Stroke Register (Riksstroke) International Journal of Stroke 2017 Oct; 12(8): 802-814
DOI: 10.1177/1747493017701154
Osooli M, Steen Carlsson K, Astermark J and Berntorp E Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement treatment: the Malmö experience Haemophilia, 2017 Sep; 23(5): e403-e408
DOI: 10.1111/hae.13302
Steen Carlsson K, Andersson E and Berntorp E Preference based valuation of treatment attributes in haemophilia A using web survey Haemophilia, 2017; 23: 894–903
DOI: 10.1111/hae.13322
Norlin JM, Calara PS, Persson U & Schmitt-Egenolf M Real-world outcomes in 2,646 psoriasis patients: One in five has PASI ≥ 10 and/or DLQI ≥ 10 under ongoing systemic therapy Journal of Dermatological Treatment, 2017 Sep; 28(6): 500-504
DOI: 10.1080/09546634.2017.1289147
Persson U En ny modell för prioritering och finansiering av läkemedel för mycket sällsynta sjukdomar Rapport till kommissionen för innovativa särläkemedel, 2017.
Calara PS, Althin R, Inglese G and Nicholas T Exploring patent activity and its potential association with healthcare outcomes: a case study of ostomy products in Sweden International Journal of Technology Assessment in Health Care, 2017; 33(2): 168-175
DOI: https://doi.org/10.1017/S0266462317000435
Gralén K, Elmér C, Broström E, Althin R and Malmberg L Clincal practice of BOTOX treatment for overactive bladder syndrome in Sweden: an assessment of resource use and external validity Scandinavian Journal of Urology, 2017; 51(5): 397-401
DOI: 10.1080/21681805.2017.1334697
Soini E, Asseburg C, Taiha M, Puolakka K, Purcaru O, Luosujärvi R Modeled health economic impact of a hypothetical certolizumab pegol risk-sharing scheme for patients with moderate-to-severe rheumatoid arthritis in Finland Accepted in Advances in Therapy, 2017;34(10):2316-32
DOI: 10.1007/s12325-017-0614-8
Jönsson B, Hofmarcher T, Lindgren P, Moen F and Wilking N Comparator Report on Patient Access to Cancer Medicines in Europe Revisited- A UK Perspective Lund, Sweden: IHE Report 2017:1

Nästa »